Current Approaches to Chronic Rhinosinusitis Management

Abstract

Chronic rhinosinusitis (CRS) is a persistent inflammatory disease of the sinonasal mucosa, significantly impacting quality of life and healthcare resources worldwide. This review synthesizes current evidence and guideline-based approaches to CRS management, outlining recent advances, clinical features, diagnostic strategies, and evolving therapeutic modalities. Emphasis is placed on pathophysiological mechanisms, phenotype-directed management, and integration of emerging biologic therapies, providing clinicians with a comprehensive foundation for optimized patient care.

Introduction

Chronic rhinosinusitis is defined by the presence of sinonasal symptoms for at least 12 weeks, associated with objective evidence of mucosal inflammation. Affecting up to 12% of the global population, CRS has profound ramifications on patient well-being, productivity, and healthcare utilization. Despite its prevalence, CRS remains heterogeneous in etiology, clinical manifestation, and response to therapy. Advances in understanding endotypes and immunopathogenesis have revolutionized contemporary management, leading to more tailored, effective interventions that align with evolving evidence and clinical guidelines.

Epidemiology / Disease Burden

CRS exhibits substantial global variation, with estimated prevalence ranging from 5% to 15% depending on diagnostic criteria and population studies. The disease is a leading contributor to outpatient otolaryngology visits and carries an annual healthcare cost exceeding billions in the United States alone. Patients often experience significant reductions in quality of life, comparable to chronic obstructive pulmonary disease and congestive heart failure. The burden is further amplified by frequent work absenteeism, impaired sleep, and comorbid conditions such as asthma and allergic rhinitis.

Pathophysiology

The pathogenesis of CRS is multifactorial, involving complex interactions between host immunity, environmental exposures, microbial colonization, and genetic predisposition. CRS is broadly categorized into CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP), with distinct immunological profiles. CRSwNP is characterized by a type 2 (Th2) inflammatory response, eosinophilia, and increased interleukin-5 and IgE levels. Conversely, CRSsNP often exhibits a mixed or predominantly neutrophilic inflammation. Epithelial barrier dysfunction, impaired mucociliary clearance, and dysbiosis of sinonasal microbiota further contribute to chronicity and refractoriness.

Risk Factors

Numerous risk factors have been implicated in the development and persistence of CRS. These include genetic susceptibility, atopic status, asthma, allergic fungal sinusitis, aspirin-exacerbated respiratory disease (AERD), smoking, environmental pollutants, and occupational exposures. Anatomical variations such as septal deviation and concha bullosa may predispose individuals by disrupting normal sinus ventilation and drainage. Immunodeficiency states, cystic fibrosis, and primary ciliary dyskinesia represent important secondary contributors in select populations.

Clinical Features

CRS typically presents with a constellation of symptoms: nasal obstruction or congestion, mucopurulent nasal discharge, facial pain or pressure, and reduction or loss of smell. The persistence of symptoms for at least 12 weeks is essential for diagnosis. Additional findings may include cough, fatigue, dental pain, and ear fullness. Physical examination via anterior rhinoscopy and nasal endoscopy often reveals mucosal edema, polyps (in CRSwNP), and purulent secretions. Symptom severity and impact on daily functioning should be systematically assessed using validated tools such as the Sino-Nasal Outcome Test (SNOT-22).

Diagnosis

Diagnosis of CRS requires the integration of clinical criteria and objective evidence of mucosal inflammation, typically demonstrated by nasal endoscopy or computed tomography (CT) imaging. Endoscopic findings include mucosal edema, polyps, and purulent discharge. CT imaging is reserved for cases with diagnostic uncertainty or preoperative planning and is characterized by mucosal thickening, opacification, and ostiomeatal complex obstruction. Microbiological assessment is indicated in refractory or complicated cases, while allergy testing and immunological work-up are considered for patients with comorbid atopy or suspected immunodeficiency.

Treatment & Management

The cornerstone of CRS management is the reduction of mucosal inflammation, restoration of sinus drainage, and prevention of recurrence. Initial therapy includes saline nasal irrigation and topical intranasal corticosteroids, which provide significant symptomatic relief and reduce mucosal edema. Short courses of systemic corticosteroids are reserved for severe exacerbations, especially in CRSwNP. Antibiotics are indicated for acute bacterial exacerbations but are not routinely recommended for chronic management. Adjunctive therapies include leukotriene antagonists, antihistamines for allergic patients, and immunotherapy in select cases. Endoscopic sinus surgery (ESS) is considered for patients refractory to maximal medical therapy, with the goal of restoring ventilation, removing polyps, and facilitating topical drug delivery. Postoperative care emphasizes continued topical therapy and endoscopic debridement to optimize long-term outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in CRS management, particularly for patients with severe, recalcitrant disease. Biologic agents targeting specific inflammatory mediators, such as anti-IL-5 (mepolizumab, reslizumab), anti-IL-4Rα (dupilumab), and anti-IgE (omalizumab), have demonstrated efficacy in reducing polyp size, improving symptoms, and decreasing the need for surgery in selected CRSwNP populations. These therapies herald a paradigm shift toward precision medicine, with ongoing trials evaluating optimal patient selection and long-term safety. Additionally, innovations in drug-eluting stents and topical delivery systems are enhancing local control of inflammation while minimizing systemic exposure.

Guideline Recommendations

International consensus statements, including those from the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) and American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), emphasize a stepwise approach to CRS management. Key recommendations include accurate phenotyping, initial medical therapy with topical corticosteroids and saline irrigation, judicious use of systemic corticosteroids and antibiotics, and consideration of ESS for refractory cases. Biologic therapy is advocated for select patients with severe CRSwNP who have failed conventional interventions. Close multidisciplinary collaboration and individualized care are essential for optimal outcomes.

Conclusion

Chronic rhinosinusitis remains a complex, multifaceted disease with considerable impact on patients and healthcare systems. Advances in understanding pathophysiology and immunological endotypes have transformed management from a uniform to a targeted, evidence-based approach. Integrating guideline-directed medical therapy, surgical intervention, and emerging biologics holds promise for improving outcomes and quality of life in affected individuals. Ongoing research and multidisciplinary care will continue to refine management strategies, with an increasing focus on precision medicine and patient-centered outcomes.